Charles Schwab Investment Management Inc. Sells 33,710 Shares of Health Catalyst, Inc. (NASDAQ:HCAT)

Charles Schwab Investment Management Inc. trimmed its position in Health Catalyst, Inc. (NASDAQ:HCAT) by 5.6% during the 3rd quarter, according to its most recent Form 13F filing with the SEC. The fund owned 573,061 shares of the company’s stock after selling 33,710 shares during the period. Charles Schwab Investment Management Inc. owned about 0.95% of Health Catalyst worth $4,665,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also bought and sold shares of the company. First Light Asset Management LLC boosted its position in Health Catalyst by 438.5% in the second quarter. First Light Asset Management LLC now owns 3,956,089 shares of the company’s stock worth $25,279,000 after purchasing an additional 3,221,408 shares during the last quarter. Impax Asset Management Group plc lifted its position in shares of Health Catalyst by 16.4% during the 3rd quarter. Impax Asset Management Group plc now owns 2,554,475 shares of the company’s stock valued at $20,793,000 after buying an additional 360,201 shares in the last quarter. Millennium Management LLC lifted its position in shares of Health Catalyst by 96.3% during the 2nd quarter. Millennium Management LLC now owns 2,413,280 shares of the company’s stock valued at $15,421,000 after buying an additional 1,184,131 shares in the last quarter. Primecap Management Co. CA lifted its position in shares of Health Catalyst by 1.1% during the 3rd quarter. Primecap Management Co. CA now owns 2,404,462 shares of the company’s stock valued at $19,572,000 after buying an additional 25,000 shares in the last quarter. Finally, Daventry Group LP lifted its position in shares of Health Catalyst by 3.9% during the 2nd quarter. Daventry Group LP now owns 2,247,053 shares of the company’s stock valued at $14,359,000 after buying an additional 84,178 shares in the last quarter. 85.00% of the stock is owned by hedge funds and other institutional investors.

Health Catalyst Stock Performance

NASDAQ HCAT opened at $7.99 on Friday. The business’s 50 day moving average price is $8.16 and its 200-day moving average price is $7.43. The company has a market cap of $486.18 million, a P/E ratio of -5.92 and a beta of 1.31. The company has a debt-to-equity ratio of 0.32, a quick ratio of 1.41 and a current ratio of 1.41. Health Catalyst, Inc. has a fifty-two week low of $5.42 and a fifty-two week high of $11.41.

Health Catalyst (NASDAQ:HCAT) last announced its quarterly earnings data on Wednesday, November 6th. The company reported $0.07 EPS for the quarter, missing the consensus estimate of $0.10 by ($0.03). The business had revenue of $76.40 million during the quarter, compared to the consensus estimate of $76.27 million. Health Catalyst had a negative net margin of 26.20% and a negative return on equity of 7.51%. The business’s revenue was up 3.5% compared to the same quarter last year. During the same period last year, the company earned ($0.22) EPS. Sell-side analysts predict that Health Catalyst, Inc. will post -0.33 earnings per share for the current year.

Analyst Ratings Changes

HCAT has been the topic of a number of analyst reports. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $16.00 price objective on shares of Health Catalyst in a research report on Friday, October 4th. JPMorgan Chase & Co. lifted their price objective on Health Catalyst from $10.00 to $13.00 and gave the stock an “overweight” rating in a research note on Wednesday, September 4th. Piper Sandler reaffirmed an “overweight” rating and issued a $12.00 price objective (up previously from $11.00) on shares of Health Catalyst in a research note on Tuesday, November 26th. Stephens lifted their price objective on Health Catalyst from $7.00 to $9.00 and gave the stock an “equal weight” rating in a research note on Thursday, November 14th. Finally, Evercore ISI lifted their price objective on Health Catalyst from $8.00 to $10.00 and gave the stock an “outperform” rating in a research note on Tuesday, October 8th. Three investment analysts have rated the stock with a hold rating and nine have given a buy rating to the stock. Based on data from MarketBeat, Health Catalyst currently has a consensus rating of “Moderate Buy” and an average price target of $11.79.

Insider Buying and Selling at Health Catalyst

In related news, COO Daniel Lesueur sold 5,209 shares of the company’s stock in a transaction on Thursday, October 3rd. The stock was sold at an average price of $7.68, for a total transaction of $40,005.12. Following the completion of the sale, the chief operating officer now directly owns 134,899 shares in the company, valued at $1,036,024.32. This represents a 3.72 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this link. Also, CFO Jason Alger sold 19,599 shares of the company’s stock in a transaction on Friday, December 6th. The stock was sold at an average price of $8.32, for a total value of $163,063.68. Following the sale, the chief financial officer now owns 86,712 shares of the company’s stock, valued at $721,443.84. This trade represents a 18.44 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 59,433 shares of company stock valued at $492,503 in the last quarter. 2.50% of the stock is owned by insiders.

Health Catalyst Company Profile

Health Catalyst, Inc provides data and analytics technology and services to healthcare organizations in the United States. It operates in two segments, Technology and Professional Services. The company provides data operating system data platform which provides clients single comprehensive environment to integrate and organize data from their disparate software systems; and analytics applications, a software analytics applications build for data platform to analyze clients face across clinical and quality, population health, and financial and operational use cases.